GA 201 - Galt Pharmaceuticals
Alternative Names: GA-201 - Galt PharmaceuticalsLatest Information Update: 28 Feb 2024
At a glance
- Originator Galt Pharmaceuticals
- Class Analgesics; Anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation; Pain
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for clinical-Phase-Unknown development in Inflammation in USA
- 28 Feb 2024 No recent reports of development identified for clinical-Phase-Unknown development in Pain in USA
- 06 Jan 2021 Clinical trials in Inflammation in USA (Galt Pharmaceuticals pipeline, January 2021)